SiNtx Technologies Inc (SINT)

[CL101]

Alright Folks, I tried my very best to compile this list of DDs from Boston, myself & others. Some of the statements we made are just opinions based on FACTs we found. Boston, can you try to compile a list of evidences/visions why Zimmer desperately needs AMDA's Si3N4 (in details please) for their growth & in many market penetrations (Spine, Hip, Knee, Dental, etc). Can someone make this a sticky post? It would be nice if all other forums or message boards' long investors can be directed to read this post for their own DDs. On other message boards, many bears are just bash AMDA with their own, same set of opinions w/o any real facts or links to back their comments!

The Connections:

Amedica & Zimmer connection starts at the very top: Sonny Bal & David Dvorak both trustees for OREF http://www.oref.org/about/governance

#1 2012 - Who the "F" was this little Amedica (The "hate" started there!?) http://www.cafepharma.com/boards/threads/three-rivers-spine.465587/ (Stryker Board) & http://www.cafepharma.com/boards/threads/wtf-amedica.493073/ (Medtronic Board) (This is the website for Ortho Experts in the field to chit chat.)

#2 2012 - The connection to Zimmer starts right here 2012 Sonny was consultant for several companies including Amedica & Zimmer: B.S.B. is a consultant for Zimmer, Inc, Medtronic, Amedica Corporation, and ConforMIS. He is also on the corporate boards for Amedica, OrthoMind, and Bonesmart.org, and is business founder and partner in the law firm BalBrenner LLC. No conflicts of interest exist in this manuscript, and authors report no proprietary or commercial interest in any product mentioned or concept discussed in this article. http://www.semarthroplasty.com/article/S1045-4527(12)00071-5/fulltext

#3 2013 - Amedica Signs Agreement with Kyocera for Commercial Manufacture of Silicon Nitride Medical Devices http://www.prnewswire.com/news-releases/amedica-signs-agreement-with-kyocera-for-commercial-manufacture-of-silicon-nitride-medical-devices-233494661.html

#4 2013- Amedica's trials started in the Netherlands under the oversight of Dr. Mark P. Arts & Dr Jasper Wolfs Cascade trial began in Sept 2013 and SNAP trial in Jan 2014. This isn’t normally an interesting fact, except that both of these surgeons receive grants from Zimmer & work as consultants for Zimmer. The authors MA (Mark Arts) and JW (Jasper Wolfs) receive research grants from Zimmer-Biomet, EIT and Intrinsics. MA and JW are consultants for Zimmer-Biomet and Silony and they receive royalties from EIT. https://link.springer.com/article/10.1007%2Fs00586-017-5079-6

#5 2014 - Sonny was no longer consultants for any other companies other than Amedica & Zimmer before taking over as CEO at Amedica
B. Sonny Bal, MD (2 – Journal of Arthroplasty; Knee; 4 – DePuy, A Johnson & Johnson Company – Anterior Total Hip Symposium, 11/2/07 at AAHKS Meeting; 5A – Zimmer; AMEDICA; 7 – Zimmer; 8- AMEDICA) https://www.aaos.org/ccc/contrib_conflicts.html

#6 2014 - Kyocera contemplates Vancouver expansion. A preliminary planning application filed last week with the city of Vancouver describes 10,000 square feet of additional manufacturing space and 1,500 square feet of associated office space. The company currently has 40,000 square feet of space at its site on Northeast Fourth Plain Boulevard http://www.oregonlive.com/silicon-forest/index.ssf/2014/06/kyocera_contemplates_vancouver.html

#7 2015, July 21 – Kyocera increases expansion of newbuilding from 10,000 to 18,000 sq ft. Plans filed with the city of Vancouver call for Kyocera to expand its 40,000-square-foot factory by more than 18,000 square feet with a two-story addition. http://www.oregonlive.com/silicon-forest/index.ssf/2015/07/kyocera_plans_vancouver_expans.html

#8 2015, July 22 - Word on the street is a merger/buyout with Amedica....any info or thoughts? (posted on a Zimmer board) http://www.cafepharma.com/boards/threads/amedica.583298/

#9 2015, July 23 - Amedica Corporation Signs Additional OEM Letter of Intent Supply Agreement Amedica Corporation (Nasdaq:AMDA), a biomaterial company that has developed silicon nitride ceramics as a material platform to manufacture and commercialize orthopedic implants, is pleased to announce that it has signed an original equipment manufacturer (OEM) letter of intent supply agreement with a leading orthopedic device design and manufacturing company. http://www.amedica.com/news-media/press-releases/detail/45/amedica-corporation-signs-additional-oem-letter-of-intent

#10 2015, Sept 9th- Amedica Corporation Adds Giuseppe Pezzotti, PhD to Its Scientific Advisory Board (i'm speculating Giuseppe is associated with Zimmer based on timing, no clear evidence found yet) Amedica Corporation (Nasdaq:AMDA), a company that develops and commercializes silicon nitride ceramics as a biomaterial platform, today announced the appointment of internationally renowned scientist Giuseppe Pezzotti, Ph.D. to its Scientific Advisory Board. Dr. Pezzotti will advise the Company on the scientific properties and clinical applications of silicon nitride, and assist Amedica in further developing its technology. http://www.amedica.com/news-media/press-releases/detail/53/amedica-corporation-adds-giuseppe-pezzotti-phd-to-its http://aaos2017.conferencespot.org/aaos63877-1.3443042/t003-1.3448845/f003-1.3448846/a087-1.3449098/p402-1.3449117 http://www.medicalnewstoday.com/articles/308784.php (Boston, he is an expert on ceramic @ Kyoto University - Did Sonny get his PHD there?)

#11 Fall 2015 - Amedica adds Sintex on as distributor in Brazil; Biomet had a foot print of an elephant in Brazil before they merged with Zimmer - Post Merger - Zimmer Biomet (ticker ZBH) http://www.biomet.com/regions/southAmerica/brazil.cfm?passedCategory=orthopedics ...http://www.sintexmedical.com.br/home

#12 2015 on - Paul Saiz, MD. Since 2005, Dr. Saiz has worked as a Consultant for Zimmer Spine. He consulted on the Zimmer Spine TM Ardis project, and he continues to lend his expertise to the company’s Trabecular metal projects. He has also consulted for Amedica Corporation, which included training Brazilian surgeons on the Valeo pedicle screw system. http://paulsaizmd.weebly.com/ & http://files.shareholder.com/downloads/ZMH/0x0x15939/5a3a0143-4c55-479c-b811-0ab84554fc36/123310.pdf (Zimmer acquired Trabecular Metal Technology from Implex Corp. for about $200 Mils - Cash + Stock)
#13 2015-2016 - Comparative Testing of Ceramic Femoral Heads for Total Hip Arthroplasty (testing begins at same location as Biomet knee testing - indirect connection) https://www.unmc.edu/orthosurgery/research/grants.html

#14 2015-2016 Product Pipeline: Hip & Knee Replacement (pg 33) (Hip testing being done at Kyoto University which has also received grants from Kyocera & Zimmer - indirect connection) https://www.sec.gov/Archives/edgar/data/1269026/000149315216010774/fwp.htm

#15 2016 - The effects of kinematically aligned total knee arthroplasty on stress at the medial tibia Kyoto University has received grants from Zimmer Biomet in relation to this article. Funding has been received by Kyoto University from Kyocera, Smith & Nephew, Mitsubishi Tanabe Pharma Corp, Chugai Pharmaceutical Co. Ltd., Bristol-Myers Squibb Co. Ltd. and Eisai Co. Ltd, Fizer Japan Inc., Astellas Pharma Inc., AbbVie GK, AYUMI Pharmaceutical Corp., Taisho Toyama Pharmaceutical Co. Ltd., and Eisai Co. Ltd., none of which is related to this article https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5301901/

#16 April 2016 - KYOCERA Breaks Ground to Expand Industrial Ceramic Manufacturing Operations in Washington State
Kyocera breaks ground of new manufacturing building 1 week after Amedica announces deal with Weigao. https://americas.kyocera.com/press-releases/press-releases_20160425.htm

#17 Nov 2016 – Amedica Announces New Sales Leadership (Dana Lyons & Ryan Long were both Zimmer VPs) http://www.amedica.com/news-media/press-releases/detail/89/amedica-announces-new-sales-leadership-and-provides & https://www.linkedin.com/in/ryanjlong/ &
https://www.linkedin.com/in/dana-lyons-a23b9550/ This 2 guys were making $ millions @ Zimmer ($25 Bil Market Cap) & switched to Amedica (a nano cap with $10 Mil Market Cap & Bashers say Amedica about to BK...LMAO..SMH)...Sounds very funny & illogical!!! Looks like they were assigned by Zimmer to go over to Amedica (Special Assignments...IMO) to prepare for the transitioning before acquisition take place. Also, in this Amedica VP search on Linked, #2 circle (Orlando Florida Area) & #5 circle (Greater New York City Area)...Could they be someone from Zimmer like Lyons & Long? http://imgur.com/a/m69QV

#18 Dec 2016 - The Effect of Cervical Interbody Cage Morphology, Material Composition, and Substrate Density on Cage Subsidence
Dr. Suh or an immediate family member has received royalties from Zimmer Biomet, is a member of a speakers’ bureau or has made paid presentations on behalf of Eli Lilly, and serves as a paid consultant to or is an employee of Amedica and Zimmer Biomet. http://journals.lww.com/jaaos/Fulltext/2017/02000/The_Effect_of_Cervical_Interbody_Cage_Morphology,.10.aspx

#19 Feb 2017 – Amedica Announces Results of Independent Femoral Head Wear Testing. This independent wear study was conducted in accordance with international standards at the Medical Technology Laboratory of the Rizzoli Orthopaedic Institute (Bologna, Italy) by Professor Aldo Toni MD under the supervision of Dr. Saverio Affatato PhD (Rizzoli Institute) with consultation and support from Professor Giuseppe Pezzotti PhD (Ceramic Physics Laboratory, Kyoto Institute of Technology, Sakyo-ku, Kyoto Japan). Amedica and Zimmer-Biomet (Tokyo Office) provided the femoral heads and acetabular liners; however, neither company actively sponsored the research. http://www.amedica.com/news-media/press-releases/detail/95/amedica-announces-results-of-independent-femoral-head-wear. Here is the details of the test: www.mdpi.com/2075-4442/4/4/35/pdf

#20 April 2017 - KYOCERA Expands Industrial Ceramic Manufacturing Operations in Washington State (new building increased 5,000 sq ft over 2016 estimate of 18,000. Head count now up to 50) The newly constructed building on the Kyocera site at 5713 N.E. Fourth Plain Boulevard expands the company’s local 40,000-square-foot manufacturing presence by more than 50 percent, to 63,000 square feet — and could create up to 50 new employment positions over the next few years. The facility currently employs approximately 140 staff members on three shifts. http://www.businesswire.com/news/home/20170420006584/en/KYOCERA-Expands-Industrial-Ceramic-Manufacturing-Operations-Washington

#21 June 2017 - Zimmer Biomet Rides on Spine Business, Knee Challenges Stay. This is in line with the strategy to grow through inorganic means by focusing on mega acquisitions. Management is also striving to develop spine portfolio in order to cash in on the opportunities....Zimmer Biomet has been of late working to strengthen its foothold in the emerging markets that provide long-term opportunities. The company's strategic investments in these regions over several quarters with a view to enhance operational and sales performance are yielding results. http://www.nasdaq.com/article/zimmer-biomet-rides-on-spine-business-knee-challenges-stay-cm800569

The most recent piece of AMDA's connection with Zimmer posted by Boston:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=132126254
================================================================================================================================================
The BO Thesis:

Puzzle piece #1 No CFO since last year 3Q 2016 - Sonny is CEO & PFO http://www.amedica.com/about/management-team

Puzzle piece #2 No Controller as well, since Apr 2017 - https://www.linkedin.com/in/aaron-stout-684bb84/

* All accounting related material is being handled by BDO - http://investors.amedica.com/all-sec-filings/content/0001493152-16-011712/form8-k.htm --- https://www.bdo.com/services/consulting/corporate-finance-ma-advisory/overview

Puzzle piece #3 No 2016 10K & 2017 1Q & even NO proxy statement too

Puzzle piece #4 Lawsuit settled: "Effective November 9, 2016, we entered into a settlement and release agreement (the “Settlement Agreement”), with each of the selling stockholders named in this prospectus in full settlement of a lawsuit filed against us on April 1, 2016 by Hampshire MedTech Partners II, GP (“Hampshire GP”), on behalf of itself and the other selling stockholders, in the Travis County, Texas 200th Judicial District Court relating to a Warrant to Purchase Shares of Common Stock issued by us to Hampshire MedTech Partners II, LP. In connection with the Settlement Agreement we issued a total of 962,380 shares of our common stock to the selling stockholders. Pursuant to the Settlement Agreement, we agreed to file the registration statement of which this prospectus is a part with the Securities and Exchange Commission (the “SEC), to register the sale or other disposition of the shares of our common stock we issued and to use our best efforts to cause the Securities and Exchange Commission to declare the registration statement effective." http://investors.amedica.com/all-sec-filings/content/0000912282-16-000919/amedica424b3_121216.htm?TB_iframe=true&height=auto&width=auto&preload=false (You guys see the timing...preparation started 3Q or 4Q last year.)

Puzzle piece #5 Global Eagle Entertainment, Inc. filed Form NT for late 10K (on 3.16.2017), but updated investors about the waiver they asked from their lender on on 5.4.2017 (Failed to deliver Financial Statements on time) https://seekingalpha.com/filing/3535091 --- Amedica NEVER update investors about the waiver to Hercules & Hercules doesn't even "bitch" about Amedica's non timely to deliver Financial Statements which required per the Loan Agreement.
***Here I have another example of a company filed Form NT 10-Q on 5.11.2017: https://seekingalpha.com/filing/3546476 ...It only took 20 calendar days, they already filed Form 8-K to update their investors about the waiver to their lender due to non timely provide Financial Statements: https://seekingalpha.com/filing/3578346

Puzzle piece #6 Funds were loading in Q1 & possibly have been loading in Q2 as well https://fintel.io/so/us/amda

Puzzle piece #7 In collaboration with its auditors, Amedica continues to consider any potential impairment in relation to certain of its long-lived assets - "long-lived assets" language in 8K on 5.26.2017 http://investors.amedica.com/all-sec-filings/content/0001493152-17-005915/0001493152-17-005915.pdf & recent 8K again on 6.9.2017 http://investors.amedica.com/all-sec-filings/content/0001493152-17-006356/ex99-1.htm?

Other companies that have LATE SEC filings on 10K or 10Q, they DON'T use the same language or phrase of "long-lived asset" auditing in their 8-K.

JRJR:
On 11.15.2016, they filed Form NT 10-Q (non timely to file 10Q)
http://www.jrjrnetworks.com/profiles/investor/secDL.asp?b=2203&c=1403085&ID=000162828016021501/0001628280-16-021501
On 11.29.2016, they filed the 8-K (like the ones amda filed) explaining the reasons why it was late. In the filing below, can't find the phrase "long-lived asset" auditing like we saw in amda's 8K:
http://www.jrjrnetworks.com/profiles/investor/secDL.asp?b=2203&c=1403085&ID=000162828016021711/0001628280-16-021711
On 3.31.2017, they filed Form NT 10-K (non timely to file 10K)
http://www.jrjrnetworks.com/profiles/investor/secDL.asp?b=2203&c=1403085&ID=000162828017003248/0001628280-17-003248
On 4.20.2017, they filed the 8-K (like the ones amda filed) explaining the reasons why it was late. I can't find the phrase "long-lived asset" audting as well! Here is the 8K they filed:
http://www.jrjrnetworks.com/profiles/investor/secDL.asp?b=2203&c=1403085&ID=000162828017003963/0001628280-17-003963

IMNP:
On 3.31.2017, they filed Form NT 10-K
https://www.sec.gov/Archives/edgar/data/1208261/000114420417018152/v463220_nt10k.htm
On 5.16.2017, they filed Form NT 10-Q
https://www.sec.gov/Archives/edgar/data/1208261/000114420417027921/v467193_nt10q.htm
On 5.26.2017, they filed Form 8K (exactly like amda's 8K to explain the non timely to file Financial Statements, but guess what...there is no such phrase about auditing "long-lived asset" language in their 8K.
http://archive.fast-edgar.com//20170526/AIAT222CZM22KTZZ2R2R2ZZH37QSZB22Z292/

JMBA:
On 3.20.2017, they filed form NT 10-K for non timely to file their 10K:
http://ir.jambajuice.com/phoenix.zhtml?c=192409&p=irol-SECText&TEXT=aHR0cDovL2FwaS50ZW5rd2l6YXJkLmNvbS9maWxpbmcueG1sP2lwYWdlPTExNDgwMDY5JkRTRVE9MCZTRVE9MCZTUURFU0M9U0VDVElPTl9FTlRJUkUmc3Vic2lkPTU3
On 3.24.2017, they filed form 8-K to explain why it was late, the language inside the 8K has no such phrase "long lived-assets" like amda's 8K:
http://ir.jambajuice.com/phoenix.zhtml?c=192409&p=irol-SECText&TEXT=aHR0cDovL2FwaS50ZW5rd2l6YXJkLmNvbS9maWxpbmcueG1sP2lwYWdlPTExNDg5ODg2JkRTRVE9MCZTRVE9MCZTUURFU0M9U0VDVElPTl9FTlRJUkUmc3Vic2lkPTU3
On 5.15.2017, they filed from NT 10-Q for non timely to file their 10Q:
http://ir.jambajuice.com/phoenix.zhtml?c=192409&p=irol-SECText&TEXT=aHR0cDovL2FwaS50ZW5rd2l6YXJkLmNvbS9maWxpbmcueG1sP2lwYWdlPTExNTk5MTgwJkRTRVE9MCZTRVE9MCZTUURFU0M9U0VDVElPTl9FTlRJUkUmc3Vic2lkPTU3
On 5.19.2017, they file form 8-K to explain why it was late, the language inside the 8K has no such phrase "long lived-assets" like amda's 8K:
http://ir.jambajuice.com/phoenix.zhtml?c=192409&p=irol-SECText&TEXT=aHR0cDovL2FwaS50ZW5rd2l6YXJkLmNvbS9maWxpbmcueG1sP2lwYWdlPTExNjA5NDc0JkRTRVE9MCZTRVE9MCZTUURFU0M9U0VDVElPTl9FTlRJUkUmc3Vic2lkPTU3

As you can see, this is 3rd example so far that proves amda's 8K really hinting the on-going audits in process is related to acquisition!

There are 2 major scenarios that they will audit long-lived assets:
#1 BK <<<<< Does amda looks like they will fold (Chapter 11)? HECK NO! This happened a lot back in 2008 crash, downturn of the market...when Compound annual growth rate (CAGR) of most companies in the negative.

#2 ACQUISITION <<<<< Measuring the fair value before sale/purchase of assets.

Am I the only ones that have this thinking of "BO" based on the language used of "long-lived assets" in their 8K? Think NOT! Coincidentally, the author in this article below has the same thought:
"When companies file these 8Ks, it’s unusual to reference long-lived assets in particular as the driving factor, and that Amedica was dressing itself up for acquisition would explain this specific reference."
https://www.insiderfinancial.com/amedica-corporation-nasdaqamda-looks-set-for-revaluation/123437/

Below is the links to 3 different reference reading material regarding "long-lived assets" auditing:

https://www2.deloitte.com/content/dam/Deloitte/us/Documents/audit/ASC/Roadmaps/us-aers-roadmap-to-reporting-discontinued-operations.pdf (For the target company)

https://media2.mofo.com/documents/1506practicepointersonfinancialstatement.pdf (For both target & acquirer companies to produce GAAP)

http://www.cheneliere.info/cfiles/complementaire/complementaire_gm/fichiers/certif/8410_fvtoolkit.pdf (Measuring fair value of a company before sale/purchase took place)

An example of 3-year book auditing before an acquisition took place:

http://www.timesunion.com/allwcm/article/Albany-Molecular-bought-by-private-firms-for-922M-11199035.php

This is their 10K/A shows they went back & audited 3 yrs for Deferred tax asset (is considered an intangible type of long-lived asset group):

http://ir.amriglobal.com/secfiling.cfm?filingID=1144204-17-25746&CIK=1065087

As you can see, in the process of being acquired...they have to go back 3 years to audit the book completely (long-lived assets, tangible, intangible like intellectual properties, deferred tax asset, aka NOLs, etc...all belong to "asset group")

Here is an example of business combinations SEC filing, pay attention to the language they used:
https://www.sec.gov/Archives/edgar/data/1123845/000112384501500005/fifth1-ksb.htm

Puzzle piece #8 "All debt will retire by January 2018, or sooner. Absent new financing, Amedica expects to be compliant with its debt covenants under the Hercules loan through July 2017." First time ever they made this type of statement about paying their debt off early! http://investors.amedica.com/all-sec-filings/content/0001493152-17-006356/ex99-1.htm (Hercules loan PREVENTS take over! As of current, they have enough cash to pay off Hercules loan instantly!)

Puzzle piece #9 Insider Holdings isn't much, but shareholders voted to increase managements option pool. Why else would management ask for 800k increase (3 fold increase)?
https://imgur.com/OxQiLeS
https://www.sec.gov/Archives/edgar/data/1269026/000149315216010411/form8-k.htm

Below is an example that showed Intermec had the same events before they were acquired by Honeywell. First thing that similar is a proxy vote scheduled for May 22, 2012 & filed April 12, 2012. The proxy contains 2 major similarities with AMDA, the election of a new Auditing firm & a significant increase to the option pool for management (original amount was 1.5 million proxy increased it to 4.5 millions or 3.7 million issuable shares):
https://imgur.com/isqVbll And
https://www.sec.gov/Archives/edgar/data/1044590/000119312512159726/d317545ddef14a.htm

The scenarios are not exactly the same as Intermec filed its 10-Q 2 days later but consider that Intermec had over 2000 employees at the time while Amedica has 30...only 3 people in accounting.

The last link is the announcement of Intermec being Acquired by Honeywell 8 months after filing of the proxy:

https://imgur.com/voCw2UU (look at the "long-lived assets" language they used) And https://www.sec.gov/Archives/edgar/data/1044590/000119312512231672/d319657dnt10q.htm

Intermec Acquired by Honeywell news: http://www.businesswire.com/news/home/20121210005706/en/Intermec-Acquired-Honeywell-600-Million

Every acquisition timing is different. A Trading Halt & BO news could come anytime & give everyone a surprise! IMO!

================================================================================================================================================

I am a big believer in AMDA's CSC & Sonny's vision for the holly grail of spinal surgery:

Our 24-month CASCADE study was a blinded, randomized clinical trial that compared outcomes of cervical fusion between our composite silicon nitride devices manufactured with an integrated core of cancellous structured ceramic (CsC), to the existing standard, i.e., PEEK (polyether ether ketone plastic) spacers filled with bone autograft.

The CASCADE study enrolled patients in a prospective trial that independently scored fusion rates and clinical outcomes at 24 months. The study was designed to compare the effects of our porous silicon nitride versus bone autograft - the patient's own bone - on patient outcomes. The silicon nitride interbody device was wetted with blood from the surgery site, but had no extrinsic bone graft material added to it. The control group was a PEEK, plastic, cage filled with bone autograft harvested during the decompressive discectomy. Results showed comparable clinical and radiographic performance between porous silicon nitride and bone autograft through a number of validated scientific clinical outcome measures.

"Porous silicon nitride is the first synthetic material to demonstrate spinal fusion outcomes that are similar to the patient's own bone," said Dr. Sonny Bal, chairman and CEO of Amedica Corporation.

This is the result of the CASCADE (24 months blind studies):
https://link.springer.com/article/10.1007%2Fs00586-017-5079-6

Even the SNAP Trial shows excellent result: "Results from Amedica’s CASCADE clinical trial showing effective spine fusion with porous silicon nitride without added bone graft are now published in the European Spine Journal. A similar trial (SNAP) compared silicon nitride to PEEK in lumbar fusion; preliminary data from the SNAP trial are consistent with previous observations that silicon nitride shows enhanced and earlier spine fusion than PEEK." Said Sonny in the filing:
https://www.sec.gov/Archives/edgar/data/1269026/000149315217006356/ex99-1.htm

The study of Valeo OL Interbody Fusion Devices for Posterior Lumbar Interbody Fusion SNAP Trial (SNAP):
https://clinicaltrials.gov/ct2/show/results/NCT01557829

Traditional way of Spine Fusion Surgery:
https://www.spine-health.com/treatment/spinal-fusion/autograft-patients-own-bone
https://www.spine-health.com/video/spine-fusion-surgery-video

CSC procedure will eliminate the need of the step in the video at 1:05 to 1:15: NO NEED TO CUT THE 2ND SITE ON PATIENTS TO GRAFT BONE!

This less invasive spinal fusion surgery procedure can ONLY be done with AMDA's unique Si3N4 Biomaterial! Check this presentation out (page 8):

http://c.eqcdn.com/_5c7526ae538a6086a4025ef13f5136d2/amedica/db/224/1039/pdf/AMDA_Investor+Presentation_Jan++2017.pdf

The above presentation, check page 15 for the comparison between 1st & 2nd Generation! Significantly Improve! Osteoconductivity increased 190% over current silicon nitride composition.

The recently obtained 2nd generation Si3N4 Worldwide Patent in many countries:
https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2017027426 (This is the priceless piece of long-lived asset!!!)

IMO, CSC will be all handled by Zimmer post acquisition. So the bashing about CSC by bears is moot point as of now.

IMO, Valeo® C+CsC using 2nd Generation Si3N4 is the future, the holly grail of spinal surgery:
CSC method will be a game changer forever! Less complicated procedures for surgeons & less risk of getting lawsuits for hospitals. Cheaper for insurance company. Greatly reduce the pain for patients (no need to harvest bone from 2nd site) & faster healing time. Most important is reducing the needs to inject invasive anti-infective drugs post surgeries (esp. peek biomaterial = very high infection rate post surgery). THIS IS A BIG THREAT TO "PEEK" BIOMATERIAL, WHICH CONTROLLING THE SPINAL SURGERY MARKET! CSC is currently approved in Europe, but lack of sale due to the corrupted industries & dirty plays by market controller "PEEK" biomaterial. Once AMDA' Si3n4 in the hand of Zimmer Biomet (vast resources in sale channels), the playing field will be balanced!

IMO, This is the theory of low pps... DO NOT SHAKE THE BUSH & ALARM THE SNAKES (smart investors out there)...dressing amda pps like a real POS...so they can accumulate more shares @ cheaper price while they bash the hell out of AMDA using many techniques:

http://boards.fool.com/paid-stock-bashers-lp-13645949.aspx

When reading conversation between posters, I always think "mole planting" like the movie "The Departed"! The smart, advance level bashers will try to create FUD (Fear, Uncertainty, Doubts) for investors that are trying to read & do their DDs!

As for comparison with TBRA acquisition scenario to AMDA's low revenue:

1. TBRA had $1 million revenue but was bought out @ $1.7 BILLIONS plus they had a FAILED drug before the BO took place.

2. You see they have an internal audit of 10Q/A before the 8K of BO news too...very similar to what is happening to amda scenario

3. The buyer saw the value of TBRA failed drug...amda' Si3n4 2nd gen is priceless worldwide patents. In addition, Weigao deals alone is in the range of $300 mils..I don't really know how much amda valuation though.

Reference links of TBRA:

Date announced BO:
http://www.investors.com/news/tobira-shares-multiply-on-1-7-billion-buyout-from-allergan/

8k announced BO:
https://seekingalpha.com/filing/3229715

10Q shows only $1 mil revenue:
https://seekingalpha.com/filing/3179433

All SEC filings before their BO news:
https://seekingalpha.com/symbol/TBRA/key-data/filings

General Info about the $200+ Mils NOLs from amda & how much it worths in case of BO:

http://www.pepperlaw.com/resource/2483/21d3

In conclusion, only god knows the real valuation of AMDA!
================================================================================================================================================
Pre-acquisition Due Diligence for the acquirer:
https://www.forbes.com/sites/allbusiness/2014/12/19/20-key-due-diligence-activities-in-a-merger-and-acquisition-transaction/#55117fb74bfc
Will there be a strategic fit between the AMDA and the buyer (Zimmer Biomet - Based on speculation)?

Zimmer just filed form SD to disclose the biomaterial they used in the yr. of 2016:
http://archive.fast-edgar.com//20170531/A322S22DZZ2RN2ZZ2HZM2MXOJRBFEZ22Z29G/
"Products that we manufacture incorporating our Trabecular MetalTM Technology contain tantalum, a necessary conflict mineral."

Tantalum is toxic & considered pretty heavy:
http://metals.comparenature.com/en/titanium-vs-tantalum/comparison-11-57-0

Further dug in & found Zimmer acquired Implex Corp to obtain Trabecular Metal Technology:
http://investor.zimmerbiomet.com/news-and-events/news/archive/24-11-2003-192536938

At first, they thought the Trabecular Metal Technology is Holly Grail of Biomaterial (Bone Void Filling):

The myths of trabecular metal: 'the next best thing to bone':

http://www.eoj.eg.net/article.asp?issn=1110-1148;year=2013;volume=48;issue=4;spage=327;epage=329;aulast=Eid

Trabecular Metal image:
https://imgur.com/6rMvYev

AMDA'Si3N4 image:
https://imgur.com/wNUcdZJ

Si3N4 has biocompatible properties:
www.ijmse.net/uploadfile/2016/0715/20160715041827481.pdf

Look alike isn't it?

IMO, Zimmer Biomet buys Si3N4 tech. to replace their current inferior biomaterial Trabecular Metal with tons of recalls from FDA is like replacing 20 years old cheap brand car with a fully loaded, luxury, full of safety features new car!

Many billions of dollars from funds pulled in ZBH lately:

https://fintel.io/so/us/zbh

Blackrock bought almost $2 BILLIONS.

FMR LLC increased position from 0 share to 5,322,721 shares!